Vollenweider FX - Search Results

1

Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.

Liechti ME, Geyer MA, Hell D, Vollenweider FX. Liechti ME, et al. Among authors: vollenweider fx. Neuropsychopharmacology. 2001 Mar;24(3):240-52. doi: 10.1016/S0893-133X(00)00199-8. Neuropsychopharmacology. 2001. PMID: 11166515

2

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).

Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Vollenweider FX, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):25-38. doi: 10.1016/s0924-977x(96)00042-9. Eur Neuropsychopharmacol. 1997. PMID: 9088882 Clinical Trial.

3

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Vollenweider FX, et al. Neuropsychopharmacology. 1997 May;16(5):357-72. doi: 10.1016/S0893-133X(96)00246-1. Neuropsychopharmacology. 1997. PMID: 9109107

4

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.

Vollenweider FX, Gamma A, Liechti M, Huber T. Vollenweider FX, et al. Neuropsychopharmacology. 1998 Oct;19(4):241-51. doi: 10.1016/S0893-133X(98)00013-X. Neuropsychopharmacology. 1998. PMID: 9718588 Clinical Trial.

5

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Vollenweider FX, et al. Among authors: vollenweider scherpenhuyzen mf. Neuroreport. 1998 Dec 1;9(17):3897-902. doi: 10.1097/00001756-199812010-00024. Neuroreport. 1998. PMID: 9875725 Clinical Trial.

6

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

Vollenweider FX, Vontobel P, Hell D, Leenders KL. Vollenweider FX, et al. Neuropsychopharmacology. 1999 May;20(5):424-33. doi: 10.1016/S0893-133X(98)00108-0. Neuropsychopharmacology. 1999. PMID: 10192823 Clinical Trial.

7

Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.

Vollenweider FX, Remensberger S, Hell D, Geyer MA. Vollenweider FX, et al. Psychopharmacology (Berl). 1999 Apr;143(4):365-72. doi: 10.1007/s002130050960. Psychopharmacology (Berl). 1999. PMID: 10367553 Clinical Trial.

8

Is a single dose of MDMA harmless?

Vollenweider FX, Gamma A, Liechti M, Huber T. Vollenweider FX, et al. Neuropsychopharmacology. 1999 Oct;21(4):598-600. doi: 10.1016/S0893-133X(99)00032-9. Neuropsychopharmacology. 1999. PMID: 10481844 No abstract available.

9

Mood state and brain electric activity in ecstasy users.

Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX. Gamma A, et al. Among authors: vollenweider fx. Neuroreport. 2000 Jan 17;11(1):157-62. doi: 10.1097/00001756-200001170-00031. Neuroreport. 2000. PMID: 10683849 Clinical Trial.

10

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. Vollenweider FX, et al. J Psychiatr Res. 2000 Jan-Feb;34(1):35-43. doi: 10.1016/s0022-3956(99)00031-x. J Psychiatr Res. 2000. PMID: 10696831 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters